FDA approves novel bioresorbable scaffold for treating chronic limb-threatening ischemia
Abbott announced the FDA has approved its novel below-the-knee, bioresorbable, drug-eluting scaffold for people with chronic limb-threatening ischemia. The approval is based on the results of the LIFE-BTK trial, presented at Transcatheter Cardiovascular Therapeutics 2023, which compared the scaffold (Esprit BTK everolimus-eluting resorbable scaffold system) with conventional balloon angioplasty